New Products In Brief
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific’s Ion stent
You may also be interested in...
People Briefs: NuVasive, Delcath, Boston Scientific, Silk Road, Si-Bone
NuVasive and Delcath Systems appoint CEOs. Boston Scientific Corp. names senior medical director, rhythm management. Silk Road Medical Inc. appoints executive VP, global sales. Si-Bone taps CFO.
ACC Previews Next Round Of Stent Wars: Ease-Of-Use Claims Will Be Key
The singular U.S. market dominance of the cobalt-chromium everolimus-eluting stent known as Xience V or Promus is likely to be threatened next year as two new next-generation products make their way to market.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.